Professor Wang Zhiren
E-mail：zhirenwang@scut.edu.cn
2024-Present South China University of Technology, Professor
2019-2024 The University of Arizona, College of Pharmacy, Postdoctoral Researcher
2017-2018 Sun Yat-Sen University, Associate Researcher
2016-2016 University of California San Diego, PostdoctoralScholar Researcher
2011-2016 Sun Yat-Sen University, School of Pharmaceutical Sciences, Ph.D
Nanomedicines,Drug delivery, Phospholipids, Liposomal drugs
The Dr. Wang’s Laboratory hasmaintained a sustained research focus on the rational design and development ofengineered phospholipid-based nanovesicles as modular drug delivery platforms.These biomimetic systems exhibit significant potential to advance tumor immunotherapythrough enhanced spatiotemporal control of immune modulation. Furthermore,their tunable physicochemical properties offer novel therapeutic paradigms fortargeted intervention in neurodegenerative pathologies. Dr. Wang has authoredover 20 peer-reviewed research articles in high-impact journals includingNature Nanotechnology, Nature Cancer, and Nature Communications, as well asleading specialty journals (Biomaterials, Journal of Controlled Release,Journal of Medicinal Chemistry). Additionally, Dr. Wang holds 4 granted patentsin China and the United States.
1. Zhiren Wang, Wenpan Li,Yanhao Jiang, Teng Ma, Mengwen Li, et al. A sphingolipid-derived Paclitaxelnanovesicle enhances efficacy of combination therapies in triple negativebreast cancer and pancreatic cancer. Nature Cancer 2025, in press.
2. Zhiren Wang, Jianqin Lu. Asphingolipid-derived paclitaxel nanovesicle for improved cancer therapy. NatureCancer 2025, in press.
3. Zhiren Wang, NicholasLittle, Jiawei Chen, Kevin Tyler Lambesis, Kimberly Thi Le, et al. Immunogeniccamptothesome nanovesicles comprised by sphingomyelin-derived camptothecinbilayers for safe and synergistic cancer immunochemotherapy. Nature Nanotechnology2021, 16, 1130-1140.
4. Zhiren Wang, Wenpan Li,Yanhao Jiang, Tuyen Ba Tran, Leyla Estrella Cordova, et al.Sphingomyelin-derived nanovesicles for the delivery of the IDO1 inhibitorepacadostat enhance metastatic and post-surgical melanoma immunotherapy. NatureCommunications, 2023, 14, 7235.
5. Zhiren Wang, Wenpan Li,Jonghan Park, Karina Marie Gonzalez, Xiangmeng Wu, et al. Cholesterol-modifiedsphingomyelin chimeric lipid bilayer for fortified therapeutic delivery. NatureCommunications, 2024, 15, 2073.
6. Zhiren Wang, Wenpan Li,Yanhao Jiang, Tuyen Ba Tran, Jinha Chung, et al. Camptothesome-basedcombination nanotherapeutic regimen for improved colorectal cancerimmunochemotherapy. Biomaterials, 2024, 306, 122477.
7. Zhiren Wang, Wenpan Li,Jonghan Park, Karina Marie Gonzalez, Aaron James Scott, et al. Camptothesomeelicits immunogenic cell death to boost colorectal cancer immune checkpointblockade. Journal of Controlled Release, 2022, 349, 929-939.
8. Zhiren Wang, Jiawei Chen,Nicholas Little, Jianqin Lu. Self-assembling prodrugnanotherapeutics for synergistic tumor targeted drug delivery. ActaBiomaterialia 2020, 111, 20-28.
9. Zhiren Wang, Karina MarieGonzalez, Leyla Estrella Cordova, Jianqin Lu. Nanotechnology-empoweredtherapeutics targeting neurodegenerative diseases. WIREs Nanomedicine &Nanobiotechnology 2023, 15, e1907.
10. Zhiren Wang, Jinhui Hu,Xiaoping Yang, Xing Feng, Xingshu Li, et al. Design, synthesis, and evaluationof orally bioavailable quinoline–indole derivatives as innovativemultitarget-directed ligands: promotion of cell proliferation in the adultmurine hippocampus for the treatment of Alzheimer’s disease. Journal ofMedicinal Chemistry 2018, 61, 1871-1894.
11. Zhiren Wang, Yali Wang,Bo Wang, Wenrui Li, Ling Huang, et al. Design, synthesis and evaluation oforally available clioquinol-moracin M hybrids as multi-target-directed ligandsfor cognitive improvement in a rat model of neurodegeneration in Alzheimer’sdisease. Journal of Medicinal Chemistry 2015, 58, 8616-8637.